Performance Study Using the OptiScanner on Healthy Diabetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to demonstrate the accuracy of the OptiScanner glucose measurement. The accuracy of the test device will be determined using plasma samples collected directly from Type 1 and Type 2 Diabetics using the OptiScanner. Blood samples will simultaneously be collected and measured on YSI 2300 STAT PLUS (YSI) made by YSI Incorporated. These results will be compared to the OptiScanner's glucose measurement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of the C8 MediSensors Optical Glucose Monitor™

NCT01726114

Diabetes Mellitus

COMPLETED NA

Performance Evaluation of an Investigational Blood Glucose Monitoring System

NCT01598610

Diabetes

COMPLETED NA

Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial

NCT01328717

Diabetes

COMPLETED NA

Performance Evaluation of Blood Glucose Monitoring System Using ISO Study Design

NCT01575080

Diabetes

COMPLETED NA

System Accuracy of the Blood Glucose Monitor for Personal Use Contour Care

NCT06037551

Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glucose and insulin IV to alter blood glucose

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have signed an Informed Consent Form for this study approved by the Institutional Review Board (IRB)
2. Have a documented onset of diabetes ³ 1 year prior to this study
3. Have Type 1 or Type 2 diabetes according to the American Diabetes Association diagnostic criteria
4. Be currently treated with insulin (all regimens) for ³ 1 year and able (as judged by Investigator) and willing to undergo a hypoglycemic challenge and a hyperglycemic challenge; oral diabetes medication in combination with insulin is allowed
5. Be at least 18 but no more than 65 years of age
6. Be willing and able to comply with the requirements of the protocol
7. Be willing to refrain from participating in any other investigational study while enrolled in this study
8. For Female Subjects: Be post-menopausal, sterilized or not of child-bearing potential, or have a negative pregnancy test and have no intention of becoming pregnant between Visit 1 and Visit 2, and be using contraceptive devices or drugs (risk of pregnancy must be lower than 1%).

Exclusion Criteria

1. Recurrent major hypoglycemia (as judged by the Investigator) or hypoglycemia requiring hospitalization within the last 12 months
2. Have a history of hypoglycemic seizure within the last year
3. Impaired hepatic function measured as AST/ALT ³ two and a half times the upper reference limit or total bilirubin two and a half times the upper reference limit based on analysis from the local laboratory, or at the Investigator's discretion
4. Impaired renal function measured as creatinine ³ 1.5 (females) mg/dL, ³ 1.7 (males) mg/dL based on analysis from the local laboratory, or at the Investigator's discretion
5. Haematocrit or electrolytes (sodium, potassium) outside of normal limits based on analysis from the local laboratory, or at the investigator's discretion.
6. Have Uric Acid \> 10 mg/dL based on analysis from the local laboratory
7. HIV positive, or Hepatitis B or C positive (blood test required). A viral load test will be done at the local laboratory for subjects with a positive Hepatitis result.
8. New York Heart Association (NYHA) Class III or IV congestive heart failure
9. Have a history of angina requiring hospitalization or a myocardial infarction within the last 12 months
10. Evidence of intermittent or sustained ventricular or supra-ventricular arrhythmias such as ventricular tachycardia, atrial fibrillation, etc. Holter monitoring may be performed to exclude arrhythmias at the discretion of the investigator.
11. Uncontrolled treated/untreated hypertension (systolic blood pressure ³ 160 mmHg and/or diastolic blood pressure ³ 100 mmHg)
12. Have active diabetic proliferative retinopathy (undergoing treatment)
13. Have active significant recurring skin infections or adhesive allergies, at the Investigator's discretion
14. Have given more than 150 mL of blood within 8 weeks prior to enrollment in this study
15. Currently taking anticoagulants, e.g. Coumadin (warfarin), Marcumar (phenprocoumon). Patients with prolonged activated PTT will not be included in this study.
16. Have received any investigational product or been treated with an invasive device within the past 30 days
17. Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation
18. Any chronic illness that, in the judgment of the Investigator, may hinder or confuse compliance with the protocol
19. Any condition (may include clinically significant screening laboratory assessments) which, in the judgement of the Investigator, may increase the risk to the subject or decrease the likelihood of achieving the objectives of the study
20. Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No